Sarah Dilley, MD
Gynecologic Oncology · Atlanta, GANPI 1053677591
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $980 of the $1,208 with a category attached, or 81.1%. 13 manufacturers reported payments, led by AstraZeneca at 36.6% of the total. Reporting peaked in 2019 at $332 and has fallen 70.2% since, to $99 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in GA, where the typical reported total is $3,080.
Across 25 payments — averaging $48.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$443
- Intuitive Surgical$150
- Tesaro, Inc.$120
- Immunogen, Inc.$117
- Genmab U.S., Inc.$101
- Seagen Inc.$99
- plus $178 from 7 others
What the payments were for
- Food & beverage$98081%
- Education$22819%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $443 |
| Intuitive Surgical | 2 | $150 |
| Tesaro, Inc. | 1 | $120 |
| Immunogen, Inc. | 1 | $117 |
| Genmab U.S., Inc. | 1 | $101 |
| Seagen Inc. | 1 | $99 |
| Merck | 3 | $57 |
| Eisai Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $25 |
| Stryker | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $18 |
| GSK | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$327
- Da Vinci Surgical System$129
- ZEJULA$120
- Elahere$117
- TIVDAK$101
How this compares
$1,208 in reported general payments places this provider in the 25th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $17,045 |
| Dexamethasone | 22 | $274 |
| Prochlorperazine Maleate | 18 | $161 |
| Ondansetron Hcl | 20 | $150 |
| Duloxetine Hcl | 13 | $149 |
| Gabapentin | 12 | $31 |
| Oxycodone Hcl | 12 | $21 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Atlanta
- Benedict BenignoAtlanta$273K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Guilherme CantuariaAtlanta$13K
- Cyril SpannAtlanta$12K
- Kevin AultAtlanta$10K
- Leda GattocAtlanta$7K
- Jennifer ScaliciAtlanta$6K
- Oi Wah YapAtlanta$3K
- Namita KhannaAtlanta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.